完全缓解弥漫大B细胞淋巴瘤患者治疗前18F-FDG PET/CT中脾脏异常的预后价值
回顾306例完全缓解弥漫大B细胞淋巴瘤患者,比较复发与非复发组的基线脾脏影像异常。多因素分析显示仅局灶性脾病变为独立预后因素(p=0.022,HR=2.843);倾向性评分匹配后局灶性脾病变仍与复发相关(p=0.003)并预测无进展生存(p=0.0004,HR=3.767)。
要点
- 治疗前基线18F-FDG PET/CT上的局灶性脾病变是完全缓解弥漫大B细胞淋巴瘤的独立预后危险因素。
- 局灶性脾病变在多因素分析中与复发相关(HR=2.843),匹配后预测无进展生存(HR=3.767)。
- 脾大及局灶性脾病变似乎与复发和无进展生存相关。
核心结论
- 局灶性脾病变被确定为弥漫大B细胞淋巴瘤预后的独立危险因素;治疗前脾大和局灶性脾病变似乎与患者复发及无进展生存相关;即使经倾向性匹配,局灶性脾病变仍显示有意义的预测价值。
研究设计与样本
- 研究纳入306例弥漫大B细胞淋巴瘤患者,分为复发组与非复发组,比较基线18F-FDG PET/CT脾脏异常,采用卡方检验、t检验、Cox比例风险回归、Kaplan-Meier曲线和log-rank检验,并以1:2比例(52:104)按年龄、性别和初始Ann Arbor分期进行倾向性评分匹配。
关键影像表现/征象
- 基线18F-FDG PET/CT评估的脾脏异常包括脾大和局灶性脾病变。
- 复发组与非复发组在脾大和局灶性脾病变方面差异有统计学意义。
诊断标准与关键数值
- Cox多因素分析中仅局灶性脾病变有统计学差异(p=0.022,HR=2.843)。
- 倾向性评分匹配后局灶性脾病变(n=20)在复发组与非复发组间仍有统计学差异(p=0.003),对无进展生存预测有重要作用(p=0.0004,HR=3.767)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To investigate whether spleen imaging characteristics of baseline 2-[18F]-fluoro-2-deoxy-d-glucose (18F-FDG) positron-emission tomography (PET)/computed tomography (CT) can help to predict the clinical outcome in complete response (CR) diffuse large B-cell lymphoma (DLBCL).
MATERIALS AND METHODS: Three hundred and six patients with DLBCL were enrolled in the study and divided into recurrence and non-recurrence groups. The splenic abnormalities were compared using the chi-square test and quantitative indexes were compared using the t-test. The Cox proportional hazard regression model was used for univariate and multivariate analysis. Kaplan-Meier curves and log-rank tests were used to compare progression-free survival (PFS). Propensity score matching (PSM) was used to match patients with and without splenic abnormalities according to age, gender, and initial Ann Arbor stage at a 1:2 ratio (52:104); then the recurrence and PFS results were compared again.
RESULTS: Age, international prognostic index (IPI), stage, splenomegaly, and focal splenic lesions were significantly different between the recurrence and non-recurrence groups. IPI, stage, baseline spleen mean standard uptake value (SUVmean)/liver SUVmean, splenomegaly, and focal lesions were selected by Cox single-factor analysis, and only focal lesions showed a statistical difference in terms of Cox multivariate analysis (p=0.022, hazard ratio [HR]: 2.843). After PSM, focal splenic lesions (n=20) were still statistically different (p=0.003) between the recurrence and non-recurrence groups, and this played an essential role in PFS forecasting (p=0.0004, HR: 3.767).
CONCLUSION: Focal splenic lesions were identified as an independent risk factor for the prognosis of DLBCL. Pretreatment splenomegaly and focal splenic lesions appeared to be related to the relapse and PFS of DLBCL patients. Focal splenic lesions still showed meaningful predictive value even with propensity matching.
引用
- Wang S, Ju H, Bai Y, et al. The prognostic value of splenic abnormalities in pretreatment 18F-FDG PET/CT in patients with complete response diffuse large B-cell lymphoma. Clin Radiol. 2023. PMID: 36805286. doi:10.1016/j.crad.2023.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。